Antitumor combination combining ave8062 and docetaxel

Details Antitumor combination combining ave8062 and docetaxel Antitumor combination combining ave8062 and docetaxel

A - Human Necessities

61

K

A61K 31/167 (2006.01) A61K 31/337 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2746475

The invention relates to a sequential antitumor combination of AVE8062, or a salt thereof, and docetaxel, characterized in that AVE8062 is administered to a patient in a dose of 10 to 50 mg/m2, and then, on a different day of the week, preferably after a 24-hour interval, docetaxel is administered in a dose of 50 to 120 mg/m2.

L'invention est relative à une combinaison antitumorale et séquentielle d'AVE8062 ou d'un sel d'AVE8062 et de docetaxel caractérisée en ce que 1AVE8062 est administré à un patient à une dose comprise entre 10 et 50 mg/m2 puis un jour différent de la semaine, de préférence après un intervalle de 24 heures, le docetaxel à une dose comprise entre 50 et 120 mg/m2.

Affiliated with

Also associated with

Rating

Antitumor combination combining ave8062 and docetaxel does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antitumor combination combining ave8062 and docetaxel, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antitumor combination combining ave8062 and docetaxel will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1558860